NCT07096947Completed
A Multifactor Prediction Model for Non-curative Outcomes in Mixed-type Early Gastric Cancer
A Multifactor Prediction Model for Non-curative Outcomes in Mixed-type Early Gastric Cancer: a Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 31 Jul 2025
Brief summary (registry, in English)
The goal of this dual-center study is to identify the most valuable predictive factors (MVPs) for non-curable mixed-type early gastric cancer (NC-MTEGC) and develop a nomogram scoring model to assist surgeons in formulating precise postoperative combined radiochemotherapy strategies in patients with mixed-type early gastric cancer (MTEGC) who have undergone radical surgical resection. The main question it aims to answer is: What are the most valuable predictive factors for NC-MTEGC, and can a nomogram scoring model developed based on these factors effectively assist in formulating precise postoperative combined radiochemotherapy strategies? Patients with MTEGC who have undergone radical surgical resection (including 160 in the training group, 151 in the internal validation set from the First Affiliated Hospital of Nanchang University, and 110 in the external test cohort from the Second Affiliated Hospital of Nanchang University) will be included in the study. The Least Absolute Shrinkage and Selection Operator (LASSO) algorithm will be used to assess key predictive indicators, a nomogram prediction model will be developed based on logistic regression, and an NC-MTEGC risk score model will be constructed. Meanwhile, the model's discriminatory ability, calibration, and clinical utility will be comprehensively validated across the three cohorts, with follow-up for relevant conditions.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 421 (actual)
- First submitted
- 8 Jul 2025
- Start date
- 18 Jan 2017
- Primary completion date
- 31 Dec 2022
- Lead sponsor
- The First Affiliated Hospital of Nanchang University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07096947
What you commit to
- Study type: Observational
- Participants enrolled: 421
- From 18 Jan 2017 to the primary completion date, 31 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received neoadjuvant therapy;
Other illness
- History of gastrectomy;
- Previous cancer or residual gastric cancer (GC);
Other
- Distant metastasis at diagnosis;
- Incomplete preoperative data;
- Undifferentiated MTEGC components;
- Missing imaging data or refusal of follow-up.
Who the study is looking for
- Mixed-type early gastric cancer (MTEGC);
- Receive a surgical procedure;
- Complete preoperative data.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of NanChang University Coordinator of this site? Confirm its status | Nanchang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.